Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Times Interest Earned (2016 - 2025)

Coherus Oncology's Times Interest Earned history spans 12 years, with the latest figure at -$20.4 for Q4 2025.

  • For Q4 2025, Times Interest Earned rose 14.06% year-over-year to -$20.4; the TTM value through Dec 2025 reached -$20.12, down 58.51%, while the annual FY2025 figure was -$20.12, 8.19% down from the prior year.
  • Times Interest Earned for Q4 2025 was -$20.4 at Coherus Oncology, down from -$19.07 in the prior quarter.
  • Across five years, Times Interest Earned topped out at -$3.12 in Q3 2023 and bottomed at -$51.47 in Q3 2021.
  • The 5-year median for Times Interest Earned is -$8.88 (2024), against an average of -$14.31.
  • The largest YoY upside for Times Interest Earned was 79.47% in 2021 against a maximum downside of 963.45% in 2021.
  • A 5-year view of Times Interest Earned shows it stood at -$6.83 in 2021, then increased by 19.63% to -$5.49 in 2022, then dropped by 18.26% to -$6.49 in 2023, then tumbled by 265.8% to -$23.74 in 2024, then grew by 14.06% to -$20.4 in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Times Interest Earned are -$20.4 (Q4 2025), -$19.07 (Q3 2025), and -$19.98 (Q2 2025).